Real-world effectiveness of remdesivir in immunocompromised patients hospitalized due to SARS-CoV-2 Infection: Insights to inform pharmacy practice

Early inpatient remdesivir initiation was associated with clinically meaningful and significant survival benefits in immunocompromised patients with COVID-19, with these associations persisting in the Omicron subvariant era. These findings highlight the potential importance of early antiviral treatment in this vulnerable population while underscoring the need for further prospective studies, including randomized controlled trials, to confirm causal effects and refine treatment strategies. Clinical pharmacists have a pivotal role in ensuring institutional protocols remain aligned with current evidence so that eligible high-risk patients consistently receive appropriate therapy.